• Explore /
  • Poster
  • / Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).

Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).

Abstract Video & Slides Poster

Authors

Gail Roboz

Gail J. Roboz

Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY

Gail J. Roboz , Andrew H. Wei , Farhad Ravandi , Christopher Pocock , Pau Montesinos , Hervé Dombret , Kimmo Porkka , Ignazia La Torre , Barry Skikne , Barry Skikne , Jianhua Zhong , Keshava Kumar , C. L. Beach , Hartmut Dohner

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01757535

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 7014)

DOI

10.1200/JCO.2021.39.15_suppl.7014

Abstract #

7014

Abstract Disclosures

Similar Posters

First Author: Farhad Ravandi

First Author: Gail J. Roboz

First Author: Louis Ross

First Author: Marouane Maaroufi